youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
GMAB:NASDAQ
Genmab A/S - ADR
$55.38
arrow_upward
+0.83%(+0.46) 1D
Nov 3, 1:31:46 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GMAB...
Open
$55.46
High
$56.50
Low
$55.18
Mkt. cap
34.74B
Avg. vol.
5.70M
Volume
1.77M
P/E ratio
43.63
52-wk high
$59.97
52-wk low
$23.62
EPS
$1.27
Beta
0.73
Shares outstanding
624.06M
No. of employees
3K
Open
$55.46
High
$56.50
Low
$55.18
Mkt. cap
34.74B
Avg. vol.
5.70M
Volume
1.77M
P/E ratio
43.63
52-wk high
$59.97
52-wk low
$23.62
EPS
$1.27
Beta
0.73
Shares outstanding
624.06M
No. of employees
3K
News stories
From web sources and news partners
GuruFocus
·
5 hours ago
Genmab's Stock Surges on Cancer Drug Breakthroughs
Yahoo Finance
·
6 hours ago
Genmab Stock Price Shock Puts 3 Oncology Biotech Names In Focus
UA.NEWS
·
7 hours ago
Genmab shares nearly double in three months after cancer drug trials — CNBC
Profile
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab Co., Ltd. in Suzhou, China. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US. Wikipedia
About Genmab A/S - ADR
CEOJan G. J. van de Winkel
Employees3.12K
Founded1999
Headquarters-
SectorBiotechnology
Websitegenmab.com
Analyst ratings
Based on 11 analysts giving stock ratings to GMAB in the past 3 months
Strong buy
Buy
10
Hold
1
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for GMAB in the last 3 months.
Highest
Current $55.38
$80.00 (+44.47%)
Average
$64.71 (+16.86%)
Lowest
$52.00 (-6.09%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Charlie Haywood Bank of America Securities | Buy | Reiterated | - | - | 11/01/2026 |
Michael Schmidt Guggenheim | Buy | Maintained | $80.00 | +44.5% | 10/29/2026 |
Gregory Renza Truist Financial | Buy | Maintained | $67.00 | +21% | 10/29/2026 |
Sean Laaman Morgan Stanley | Hold | Reiterated | $57.00 | +2.9% | 10/30/2026 |
Judah Frommer Morgan Stanley | Hold | Maintained | $57.00 | +2.9% | 10/30/2026 |
Ram Selvaraju H.C. Wainwright | Buy | Reiterated | $70.00 | +26.4% | 10/30/2026 |
Unknown Analyst Goldman Sachs | Buy | Maintained | $62.00 | +12% | 10/29/2026 |
Asthika Goonewardene Leerink Partners | Buy | Reiterated | $65.00 | +17.4% | 10/29/2026 |
Yaron Werber TD Cowen | Buy | Reiterated | $52.00 | -6.1% | 10/26/2026 |
Matt Phipps William Blair | Buy | Maintained | - | - | 10/23/2026 |
Benjamin Jackson CFA Jefferies | Buy | Maintained | - | - | 08/07/2026 |
James Gordon CFA Barclays | Buy | Maintained | - | - | 08/07/2026 |
Rajan Sharma Goldman Sachs | Buy | Maintained | DKK 2,400.00 | +4,234.1% | 08/07/2026 |
Eva Fortea Verdejo Wells Fargo | Buy | Reiterated | $40.00 | -27.8% | 06/29/2026 |
Kalpit Patel Wolfe Research | Buy | Maintained | $32.00 | -42.2% | 06/14/2026 |
Next call in 46:18:43
Thu, Nov 5, 12:00 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (DKK)
- GAAP EPS / Est. (DKK)
- / DKK 23.00
Revenue / Est. (DKK)
- / 8.06B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in DKK
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in DKK | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|
Revenue | 4.68B | 4.14B | 5.40B | 5.54B |
Cost of goods sold | - | - | - | 273.00M |
Cost of revenue | - | - | - | 273.00M |
Research and development expenses | - | - | - | 2.28B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | - | - | - | 865.00M |
Operating expense | - | - | - | 3.15B |
Total operating expenses | - | - | - | 3.42B |
Operating income | - | - | - | 2.12B |
Other non operating income | - | - | - | - |
EBT including unusual items | - | - | - | 1.72B |
EBT excluding unusual items | - | - | - | 1.59B |
Income tax expense | - | - | - | 453.00M |
Effective tax rate | - | - | - | 26.35% |
Other operating expenses | - | - | - | - |
Net income | - | - | - | 1.27B |
Net profit margin | - | - | - | 22.85% |
Earnings per share | 9.67 | - | - | 19.81 |
Interest and investment income | - | - | - | 162.00M |
Interest expense | - | - | - | -18.00M |
Net interest expenses | - | - | - | 144.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | - | - | - | 2.20B |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events